HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by YAMASAKI, H. Articles by NAGATA, Y. Search for Related Content PubMed PubMed Citation Articles by YAMASAKI, H. Articles by NAGATA, Y.

Body Fat Distribution and Body Composition During GnRH Agonist Therapy

From the Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.

Address reprint requests to: Hideki Yamasaki, MD, Department of Obstetrics and Gynecology, Kagoshima University, Faculty of Medicine, 8-35-1 Sakuragaoka, 890-8520 Kagoshima, Japan

Objective: To identify the effects of GnRH agonist therapy on body composition (lean and fat mass components) and body fat distribution.

Methods: Fifteen women with uterine leiomyomas were given a GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Weight, height, and body mass index (BMI, weight/height²) were recorded. Regional and total body composition, trunk-leg fat ratio, bone mineral density of the lumbar spine (L2–L4), and total body were assessed by whole-body scanning with dual-energy x-ray absorptiometry before and after treatment. Uterine volume was measured by transabdominal ultrasonography.

Results: The mean (± standard deviation [SD]) lean mass of total body, trunk, and leg decreased significantly (36.3 ± 4.9 to 35.4 ± 4.4 kg, P < .01; 18.8 ± 2.8 to 18.1 ± 2.8 kg, P < .05; and 11.4 ± 1.8 to 11.1 ± 1.6 kg, P < .05; respectively), whereas body fat mass, percentage of body fat, and trunk fat mass increased significantly (20.8 ± 4.8 to 21.8 ± 4.6 kg, P < .01; 34.9 ± 5.9 to 36.5 ± 5.2%, P < .01; and 8.6 ± 3.0 to 9.3 ± 3.0 kg, P < .01; respectively). Trunk-leg fat ratio increased significantly (1.03 ± 0.32 to 1.12 ± 0.33, P < .05). Weight, BMI, arm tissue composition (lean and fat mass components), and leg fat mass did not change during 4 months of GnRH agonist therapy. Bone mineral density and uterine volume decreased significantly.

Conclusion: Hypogonadism by GnRH agonist therapy induces lean mass loss, increased adiposity overall, and upper body fat accumulation.

This article has been cited by other articles:

				M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]

				M. J. Toth, C. K. Sites, D. E. Matthews, and P. R. Casson Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein turnover in women Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E483 - E490. [Abstract] [Full Text] [PDF]

				D. S. Day, W. S. Gozansky, R. E. Van Pelt, R. S. Schwartz, and W. M. Kohrt Sex Hormone Suppression Reduces Resting Energy Expenditure and {beta}-Adrenergic Support of Resting Energy Expenditure J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3312 - 3317. [Abstract] [Full Text] [PDF]

				Medical Menopause Increases Upper-Body Fat and Decreases Lean Body Mass Journal Watch Women's Health, April 17, 2001; 2001(417): 3 - 3. [Full Text]